

PRESS RELEASE

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer

Oxford, UK, 27 May 2025 – Nucleome Therapeutics ('Nucleome' or 'the Company'), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect.

Bhavna brings nearly two decades of experience across biotechnology, investment banking, and strategic consultancy to Nucleome. In her role, she will lead corporate and business development activities including developing and executing the business development strategy, identifying and pursuing strategic business opportunities aligned with Nucleome's vision, and supporting company growth and financing.

Prior to Nucleome, Bhavna was Chief Business Officer and Board Director at C4X Discovery where she played a critical role in a series of successful licensing deals and partnerships, as well as driving business growth and capital raising as part of the Executive Management team. Previous to this, Bhavna held corporate and commercial roles at Lehman Brothers, Nomura International, PwC and Cancer Research UK. Bhavna holds a First Class degree in Biochemistry from Oxford University.

Dr Mark Bodmer, CEO of Nucleome, said: *"I am delighted to welcome Bhavna to Nucleome, with her great breadth of experience and ability. Our proprietary lab-plus-machine learning technology is a transformative use of human genetics to discover the molecular basis of disease. This is yielding an emerging pipeline of first-in-class, highly differentiated, inflammatory disease programs. Bhavna will play an essential role in the next phase of company growth with outstanding scientific, clinical and commercial execution of the pipeline and technology".*

ENDS

Contact information

Optimum Strategic Communications

Mary Clark, Vici Rabbetts, Joshua Evans

nucleome@optimumcomms.com

+44 (0) 20 8078 4357

Notes to Editors

About Nucleome Therapeutics

Nucleome is using breakthrough genomics technologies to discover first-in-class antibody therapeutics for inflammatory diseases. The approach is based solely on human disease genetics and biology. Nucleome is able, for the first time, to reveal molecular mechanisms of disease and select drug targets using human genetic variants in the non-coding genome that alter

PRESS RELEASE

gene expression. The Company's proprietary 3D genomics combines lab and machine learning technologies which can be applied to any set of disease-associated variants.

Lead program NTP464 is an antibody that activates an inflammation checkpoint. NTP464 stimulates natural cellular processes of inflammation resolution, a new principle in the treatment of inflammation with huge potential patient benefit. Other multiple targets based on the genetics of inflammatory diseases are in discovery.

Nucleome is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. ("JJDC"), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Business Bank; and founding investor Oxford Science Enterprises.

Visit our website to find out more at: www.nucleome.com